ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study in MPS VI to Assess Safety and Efficacy of Odiparcil (iMProveS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03370653
Recruitment Status : Recruiting
First Posted : December 12, 2017
Last Update Posted : December 6, 2018
Sponsor:
Information provided by (Responsible Party):
Inventiva Pharma

Brief Summary:

Mucopolysaccharidoses (MPS) are a group of rare inherited disorders characterized by a deficiency of lysosomal enzymes responsible for the normal degradation of glycosaminoglycans (GAGs). Medical need for treatment of MPS is still very high due to the poor penetration of the recombinant enzymes into the blood brain barrier as well as the ocular barriers and into tissues that are poorly vascularized, such as cartilages and bones. Odiparcil is an orally active compound that allows the synthesis of soluble glycosaminoglycans (GAGs), mainly chondroitin sulfate (CS) and dermatane sulfate (DS). The neosynthesized solubles GAGs are then excreted in urine. By diverting endogenous GAG synthesis to the synthesis of soluble odiparcil linked GAGs, odiparcil should decrease the intracellular pool of GAGs and consequently decrease the lysosomal GAG accumulation.

The primary objective of the study is to assess the safety and efficacy of two doses of odiparcil in MPS VI patients and to provide evidence to enable the selection of the relevant dose of odiparcil for phase III study. The secondary objective of this study is to characterize the dose response, PK and PD of odiparcil.


Condition or disease Intervention/treatment Phase
Mucopolysaccharidosis VI Drug: Odiparcil Other: Placebo Phase 2

Detailed Description:

Study design: This phase IIa study consists of 2 parts performed sequentially: a preliminary safety assessment followed by the core study with a double-blind, randomized, dose-ranged cohort of patients receiving Enzyme Replacement Therapy (ERT) and an open-label cohort of patients not receiving ERT.

Preliminary safety assessment (N=2): open-label, escalating dose (2 doses) study. If acceptable safety profile is achieved, patients will be then included in the open-label arm of the core study.

Core study

Core study will be conducted on 2 populations in parallel:

  • A first cohort (N=18): MPS VI patients receiving ERT assigned in 3 arms:

    • Placebo (N=6)
    • Odiparcil 500 mg per day (250 mg BID) (N=6)
    • Odiparcil 1000 mg per day (500 mg BID) (N=6).
  • A second cohort (N=6): MPS VI patient not receiving ERT (odiparcil 1000 mg per day (500 mg BID)).

Study duration: The overall study duration will be 20 months, including the 10-month enrolment period.

For each patient, the study duration will be:

  • Preliminary safety assessment: 6 weeks including a 4-week run-in period followed by 2-week treatment period. Then, patients will go on treatment period in core study.
  • Core study: 34 weeks including a 4-week run-in period followed by 26-week treatment period and 4-week of follow-up.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Preliminary safety assessment (N=2): an open-label, escalating dose (2 doses) study.

Core study: conducted on 2 populations in parallel:

  • A first cohort (N=18): MPS VI patients receiving ERT assigned in 3 arms:

    • Placebo (N=6)
    • Odiparcil 500 mg per day (250 mg BID) (N=6)
    • Odiparcil 1000 mg per day (500 mg BID) (N=6).
  • A second cohort (N=6): MPS VI patients not receiving ERT (odiparcil 1000 mg per day (500 mg BID)).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Placebo
Primary Purpose: Treatment
Official Title: A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI
Actual Study Start Date : December 13, 2017
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : March 2020


Arm Intervention/treatment
Experimental: Double-blind - odiparcil 1000 mg per day
2 tablets of odiparcil 250 mg per os, twice daily (BID)
Drug: Odiparcil
Investigational product: odiparcil 250 mg tablets

Experimental: Double-blind - odiparcil 500 mg per day
1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)
Drug: Odiparcil
Investigational product: odiparcil 250 mg tablets

Other: Placebo
Comparator: placebo tablets similar to odiparcil 250 mg tablets

Placebo Comparator: Double-blind - placebo
2 tablets of placebo per os, twice daily (BID)
Other: Placebo
Comparator: placebo tablets similar to odiparcil 250 mg tablets

Experimental: Open Label - odiparcil 1000 mg per day
2 tablets of odiparcil 250 mg per os, twice daily (BID)
Drug: Odiparcil
Investigational product: odiparcil 250 mg tablets




Primary Outcome Measures :
  1. Number of patients with modified clinical signs [ Time Frame: 26 weeks ]
    Changes in physical examination and vital signs

  2. Number of patients with modified biological values [ Time Frame: 26 weeks ]
    Change from baseline in laboratory safety tests (coagulation, liver enzymes and crystalluria) 12-lead-ECG and bone biomarkers.

  3. Incidence of AEs/SAEs [ Time Frame: 26 weeks ]
    Incidence of AEs/SAEs, patient withdrawals from study due to AEs/SAEs,

  4. 12-lead ECG [ Time Frame: 26 weeks ]
    Change from Baseline in ECG


Secondary Outcome Measures :
  1. Mobility: 6-minute walk test [ Time Frame: 26 weeks ]
    Change from baseline in 6-minute walk test

  2. Mobility: 9-hole PEG test [ Time Frame: 26 weeks ]
    Change from baseline in 9-hole PEG test

  3. Mobility: range of motion of the shoulder [ Time Frame: 26 weeks ]
    Change from baseline in range of motion of the shoulder

  4. Pain assessment [ Time Frame: 26 weeks ]
    Change from Baseline in Brief Pain Inventory (BPI)

  5. Respiratory function [ Time Frame: 26 weeks ]
    Change from Baseline in FEV1

  6. Respiratory function [ Time Frame: 26 weeks ]
    Change from Baseline in FVC

  7. Respiratory function [ Time Frame: 26 weeks ]
    Change from Baseline in MVV

  8. Cardiac and vascular function [ Time Frame: 26 weeks ]
    Change from Baseline in echocardiogram

  9. Cardiac and vascular function [ Time Frame: 26 weeks ]
    Change from Baseline in carotid intima media thickness Odiparcil concentration remaining in patient plasma 12 hours following the last intake of investigational product at visits V4 and V7. An identification of odiparcil metabolites in plasma at visit V2.

  10. Audiology assessments [ Time Frame: 26 weeks ]
    Change from Baseline in pure tone audiometry

  11. Audiology assessments [ Time Frame: 26 weeks ]
    Change from Baseline in whisper voice test

  12. Ophthalmology assessments [ Time Frame: 26 weeks ]
    Change from Baseline in corneal opacification

  13. Ophthalmology assessments [ Time Frame: 26 weeks ]
    Change from Baseline in level of retinopathy

  14. Ophthalmology assessments [ Time Frame: 26 weeks ]
    Change from Baseline in optic nerve involvement,

  15. Ophthalmology assessments [ Time Frame: 26 weeks ]
    Change from Baseline in intra-ocular pressure

  16. Ophthalmology assessments [ Time Frame: 26 weeks ]
    Change from Baseline in visual acuity

  17. Quality of life questionnaires [ Time Frame: 26 weeks ]
    Change from Baseline in EQ-5D-5L questionnaires. 5 dimensions scored on a 5-point scale will be assessed: mobility, self-care, usual activities, pain/discomfort, anxiety/depression

  18. Quality of life questionnaires [ Time Frame: 26 weeks ]
    Change from Baseline in Zarit caregiver burden questionnaires. Scale in 22 items scored on a 5-point scale with 0 = never and 5 = nearly always

  19. Quality of life questionnaires [ Time Frame: 26 weeks ]
    Change from Baseline in Fatigue Severity Scale questionnaires. 9 questions scored on a 7-point scale with 1 = strongly disagree and 7= strongly agree

  20. Pharmacokinetics: odiparcil concentration in plasma [ Time Frame: 12 hours ]
    Odiparcil concentration in plasma at visit V2 (up to 12 hours post dose).

  21. ¨Pharmacodynamics: GAG concentrations [ Time Frame: 26 weeks ]
    GAG concentration in leukocytes isolated from peripheral

  22. ¨Pharmacodynamics: GAG concentrations [ Time Frame: 26 weeks ]
    GAG concentrations in urine

  23. Pharmacodynamics: GAG concentrations [ Time Frame: 26 weeks ]
    GAG concentrations in skin

  24. ¨Pharmacodynamics: anti-thrombin activity IIa [ Time Frame: 26 weeks ]
    Change from Baseline in anti-thrombin activity IIa in plasma

  25. ¨Pharmacodynamics: Thrombin Generation Assay (TGA) [ Time Frame: 26 weeks ]
    Change from Baseline in TGA in plasma



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Male or female gender.
  2. Age ≥16 years.
  3. Diagnosis of MPS VI, demonstrated by a reduced Arylsulfatase B (ARSB) activity relative to the normal range of the laboratory performing the assay in either white blood cells or fibroblast culture or confirmation of two known disease causing mutations in the ARSB gene.
  4. Urine GAG above upper limit of normal (ULN) based on historical data.
  5. Willing and able to provide written, dated, signed informed consent, or in the case of subjects age < 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures or study assessment.
  6. Able to comply with all study procedures.
  7. Women with childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must agree to use a highly effective method of birth control during the study and at least 4 weeks after last administration. The following can be considered to be examples of highly effective methods of contraception preferably with low user dependency:

    • Combined (estrogen and progestogen containing hormonal contraception) associated with inhibition of ovulation (oral, intravaginal, or transdermal)
    • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable )
    • intrauterine device (IUD)1
    • intrauterine hormone-releasing system (IUS) 1
    • Bilateral tubal occlusion1
    • Vasectomised partner1
    • Sexual abstinence These methods of contraception must be supplemented with a barrier method (preferably male condom).

Women with childbearing potential are required to have a confirmed negative blood pregnancy test before starting medication administration at baseline (V0). Women with childbearing potential agree to repeat blood pregnancy tests at visits in hospital (V2, V4, V7 and V8) and to perform urine pregnancy test before each phone call visit (V3, V5 and V6).

Inclusion criteria for ERT treated group:

1. Patients with MPS Type VI receiving enzyme replacement therapy (Naglazyme) for at least 6 months on the licensed dosage or as per local guidelines.

Inclusion criteria for not ERT treated group:

Patients with MPS Type VI not receiving enzyme replacement therapy for the following reasons:

  1. Patients previously treated with ERT but have discontinued for more than 3 months either due to medical decision or personal choice
  2. Patients allergic to ERT therapy
  3. Patients that have had a previous hematopoietic stem cell transplant (HSCT)
  4. Patients not treated with ERT i.e. treatment naïve

Exclusion criteria:

Exclusion criteria for the entire cohort:

  1. Use of any investigational product or investigational medical device within 30 days prior to screening. This will include product bought over the counter specifically compounds like genistein and pentosane polysulphate which may not be considered as investigational products by patients and some health care professionals.
  2. Concurrent disease or condition that would interfere with study participation or pose a safety concern for example patient with: severe cardiac insufficiency as define NYHA class > II, and severe restrictive chronic respiratory insufficiency as reflected by serum [HCO3-] ≥28 mEq/L.
  3. Subjects who had surgery within 3 months before study starts, or for whom surgery is planned during study period.
  4. Patient with spinal cord compression requiring surgical intervention.
  5. Subjects with the following liver test anomalies: any ALT, AST > 3xULN or bilirubin >1.5xULN (except if Gilbert syndrome) at screening visit.
  6. Evidence of an immunosuppressive state, including known HIV infection, agammaglubilinemias, T-Cell deficiencies.
  7. Subjects with history of chronic infections, including but not limited to subjects with past history of viral hepatitis C, or B, with recent history of serious or life-threatening infection or any current signs or symptoms that may indicate infection at visit V-1 of study as per investigators clinical judgement.
  8. History of malignant cancer except of cervical carcinoma in situ, basal cell carcinoma, dermatological squamous cell carcinoma.
  9. Subjects with significant haematologic abnormalities, such as haemoglobin <8 g/dL, or WBC<2000 /mm3 or absolute neutrophil count <1300 /mm3, or platelet <30.000 /mm3.
  10. International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) or thrombin time (TT) values above the laboratory reference range at screening. For patients on anti-coagulants, they should be within their target effect on INR and be stable.
  11. Any history of bleeding diathesis
  12. Patient with coexistence of corneal pathologies other than corneal clouding (e.g. exposure keratopathy)
  13. An unwillingness on the part of male patients to abstain from sexual intercourse with pregnant or lactating women; or an unwillingness to use highly effective form of birth control if engaging in sexual intercourse with a woman who could become pregnant from the time of the first dose of study medication until completion of follow-up procedures.
  14. An unwillingness on the part of female patients to use highly effective form of birth control2 if engaging in sexual intercourse and to have a monthly pregnancy test during treatment and until completion of follow-up procedures.
  15. Pregnant or lactating women.
  16. Have a known hypersensitivity to any of the ingredients or excipients of the IMP including: Microcrystalline Cellulose, Povidone, Sodium starch glycolate (type A), Magnesium stearate, Opadry™ II 85F18422

Exclusion criteria for ERT treated group:

1. Previous hematopoietic stem cell transplant (HSCT)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03370653


Contacts
Contact: Marie-Paule RICHARD, MD +33(0) 344 807 642 Marie-Paule.RICHARD@inventivapharma.com
Contact: Véronique BERGER +33(0) 660 741 275 veronique.berger@inventivapharma.com

Locations
France
Hôpital Femme-Mère-Enfant Recruiting
Bron, France, 69500
Contact: Nathalie Guffon-Fouilhoux, MD    00 33 4 72 12 95 37    nathalie.guffon-fouilhoux@chu-lyon.fr   
Contact: Nathalie Reynes       nathalie.reynes@chu-lyon.fr   
Germany
Villa Metabolica Not yet recruiting
Mainz, Germany, 55131
Contact: Julia B Hennermann, MD    +49 (0) 6131 17-5754    Julia.Hennermann@unimedizin-mainz.de   
Contact: Sabrina Meudt       sabrina.meudt@unimedizin-mainz.de   
Portugal
Centro Hospitalar S. João Not yet recruiting
Porto, Portugal, 4200-319
Contact: Elisa Leao-Teles, MD    +351 02 981 0097    e.leaoteles@gmail.com   
Contact: Ana Marta Rodrigues       anamartapadrao@hotmail.com   
United Kingdom
Royal Free Hospital Recruiting
London, United Kingdom, NW3 2QG
Contact: Derralynn Hughes, MD    +44 2077940500 ext 22492    derralynnhughes@nhs.net   
Contact: Allison Warwick    +44 2077940500 ext 22486    derralynnhughes@nhs.net   
Sponsors and Collaborators
Inventiva Pharma
Investigators
Principal Investigator: Derralynn HUGHES, MD Royal Free Hospital, London UK
Principal Investigator: Julia HENNERMANN, MD Villa Metabolica, Mainz GERMANY
Principal Investigator: Nathalie GUFFON-FOUILHOUX, MD Hôpital Femme-Mère-Enfant
Principal Investigator: Elisa LEAO-TELES, MD Centro Hospitalar S. João, Porto, Portugal

Additional Information:
Responsible Party: Inventiva Pharma
ClinicalTrials.gov Identifier: NCT03370653     History of Changes
Other Study ID Numbers: IVA_01_ODI_HMPS_17_002
First Posted: December 12, 2017    Key Record Dates
Last Update Posted: December 6, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Inventiva Pharma:
MPS VI
Lysosomal disease
Glycoaminoglycans (GAG)
Odiparcil

Additional relevant MeSH terms:
Mucopolysaccharidoses
Mucopolysaccharidosis VI
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Mucinoses
Connective Tissue Diseases
Metabolic Diseases